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The tumor-modulatory effects of Caspase-2 and Pidd1
do not require the scaffold protein Raidd
L Peintner1, L Dorstyn2, S Kumar2, T Aneichyk3, A Villunger*,1 and C Manzl*,1,4
The receptor-interacting protein-associated ICH-1/CED-3 homologous protein with a death domain (RAIDD/CRADD) functions as a
dual adaptor and is a constituent of different multi-protein complexes implicated in the regulation of inflammation and cell death.
Within the PIDDosome complex, RAIDD connects the cell death-related protease, Caspase-2, with the p53-induced protein with a
death domain 1 (PIDD1). As such, RAIDD has been implicated in DNA-damage-induced apoptosis as well as in tumorigenesis. As
loss of Caspase-2 leads to an acceleration of tumor onset in the Eμ-Myc mouse lymphoma model, whereas loss of Pidd1 actually
delays onset of this disease, we set out to interrogate the role of Raidd in cancer in more detail. Our data obtained analyzing
Eμ-Myc/Raidd− /−mice indicate that Raidd is unable to protect from c-Myc-driven lymphomagenesis. Similarly, we failed to observe
a modulatory effect of Raidd deficiency on DNA-damage-driven cancer. The role of Caspase-2 as a tumor suppressor and that of
Pidd1 as a tumor promoter can therefore be uncoupled from their ability to interact with the Raidd scaffold, pointing toward the
existence of alternative signaling modules engaging these two proteins in this context.
Cell Death and Differentiation (2015) 22, 1803–1811; doi:10.1038/cdd.2015.31; published online 10 April 2015
A number of mechanisms have evolved to trace and remove
potentially dangerous cells. Deregulation of the induction of
apoptosis upon oncogenic stress, for example, can facilitate
the accumulation of cells prone to undergo malignant
transformation. Cell death by apoptosis depends on the
cascade-like activation of proteases of the Caspase family.1
Among these, the evolutionarily most conserved protease,
Caspase-2, turns out to be a potent tumor suppressor in
mice2–7 and correlative expression data support a conserved
role in human cancer.8–13
Early studies suggested that Caspase-2 interacts with other
proteins for its activation (e.g., after genotoxic stress), but the
protease seems also able to auto-activate cell death on its own
when present in sufficiently high concentration.14–18 The most
prominent Caspase-2-containing protein complex was dubbed
the ‘PIDDosome’ and described to contain the p53-induced
protein with a death domain (PIDD1) and receptor-interacting
protein-associated ICH-1/CED-3 homologous protein with a
death domain (RAIDD, also known as CRADD).19 Although the
molecular details of the pro-apoptotic potential of Caspase-2 are
still discussed and alternative roles in the DNA-damage
response, cell cycle arrest or sensor of metabolic stress are
mechanistically poorly understood, Caspase-2 clearly limits
tumorigenesis in different settings. These include aberrant
expression of c-Myc in B cells3,4 or deletion of the DNA-
damage response regulator, ataxia telangiectasia mutated
kinase (ATM), both driving lymphomagenesis6 as well as
overexpression of the Her2/ErbB2 oncogene in breast5 or
that of mutated KRAS in the lung epithelium, driving
carcinoma formation.7 One of these studies, addressing also
the role of Pidd1 in c-Myc-driven lymphomagenesis, revealed
an unexpected oncogenic role for Pidd1, thereby questioning
the physiological relevance of the PIDDosome complex in
Caspase-2-mediated cell death and tumor suppression.4,20
However, the exact role of the scaffold protein Raidd within
these processes remains unaddressed so far.
Raidd, a bipartite adapter containing a death domain (DD)
and a caspase-recruitment domain (CARD) was first
described to bind to the DD-containing kinase RIPK1 and
the C. elegans caspase CED-3,21 supporting a role in cell
death initiation. Subsequently, the interaction of Caspase-2
and Raidd was biochemically proven22 and proposed
to be required for Caspase-2 autoprocessing preceding
its activation.19 More recent studies propose an anti-
inflammatory role for Raidd through suppression of nuclear
factor kappa-light-chain enhancer (NF-κB) activation and
cytokine production upon T-cell receptor stimulation by
negatively interfering with the Carma1/Malt1/Bcl-10 signaling
complex.23,24
First evidence for a potential role of RAIDD in human cancer
was discovered in a biochemical screen using mantle cell
lymphomas, which detected a downregulation of RAIDD
by microarray analysis,10 whereas others reported on
RAIDD-linked multidrug resistance in osteosarcoma cells.25
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Furthermore, tumor cell apoptosis induced by inhibitors of
histone de-acetylases in treatment-resistant adult T-cell
leukemia lines reportedly required Caspase-2 and Raidd.26
It is also reported that the Caspase-2/Raidd axis is necessary
after ER stress, for example, in the course of infection with the
oncolytic maraba virus.27
Taken together, these studies support a role for RAIDD in
drug-induced cancer cell death as well as in tumor suppres-
sion, most likely linked to its role as a direct activator of
Caspase-2. Alternatively, RAIDDmay negatively interfere with
PIDD- or BCL10-regulated NF-κB signaling23,24,28 and
thereby suppress pro-tumorigenic inflammation. To address
the role of Raidd in tumorigenesis in more detail, we exploited
different mouse models where we induced thymic lymphomas
by γ-irradiation, fibrosarcomas by 3-methylcholanthrene
(3-MC) injection or B-cell lymphomas by aberrant expression
of the c-Myc proto-oncogene. Our results suggest that Raidd is
not a suppressor of tumors in the mouse models tested.
Results
Loss of Raidd has no impact on tumor formation after
DNA damage. As Raidd was reported to have a role in DNA-
damage-induced apoptosis because of its ability to form a
complex with Pidd1 and Caspase-2,19 we used different
cancer models to evaluate the impact of Raidd in tumorigen-
esis induced by DNA lesions. Induction of thymic lymphomas
was triggered in 4-week-old mice by repeated low-dose
irradiation (1.75 Gy). As reported before, tumor formation was
significantly accelerated in p53+/− mice when compared with
wild-type (wt) controls, showing a mean survival of 115 and
207 days, respectively. Absence of Raidd, however, had no
effect on the onset of tumorigenesis (Figure 1a) or tumor
immunophenotype (data not shown) and animals developed
thymic lymphomas with a mean survival of 190 days, similar
to their wt littermates (P= 0.37).
In another tumor model, we treated adult mice with a single
injection of 3-MC causing the formation of bulky adducts in
DNA leading to fibrosarcoma formation within 6 months. As
reported before,29 p53+/− mice developed 3-MC-induced
sarcomas significantly earlier but loss of Raidd failed to
accelerate tumor onset when compared with wt controls
(Figure 1b; P=0.97).
Together with our previously published data4 this demon-
strates that the PIDDosome, and each of its components
individually, are unable to prevent DNA-damage-induced
tumor formation inflicted by γ-irradiation or bulky DNA-
adduct formation.
c-Myc-induced lymphomagenesis is limited by Caspase-2
in a Raidd-independent manner. Caspase-2 and Pidd1
were reported to modulate lymphomagenesis in Eμ-Myc
mice, a model somewhat mimicking human Burkitt lymphoma.4
Hence, we introduced Raidd deficiency into Eμ-Myc trans-
genic animals to explore its impact on tumorigenesis caused
by oncogenic stress. Excess proliferation by aberrant c-Myc
expression in premalignant mice is usually counterbalanced
by increased cell death rates providing a rational why loss of
pro-apoptotic proteins, for example, of the BH3-only group,
accelerates disease onset.30–33
To evaluate the role of Raidd early in disease development,
the B-cell subset composition was assessed in premalignant
Eμ-Myc/Raidd− /− mice. In line with published data,4,32,34,35
the numbers of B220+IgM− pro/pre-B cells were increased in
bone marrow and spleen, whereas numbers of mature B cells
were diminished in the periphery of Eμ-Myc mice when
compared with wt controls (Figure 2a). However, no other
gross alterations within the B-cell composition and distribution
in Eμ-Myc mice specifically lacking Raidd were noted.
To monitor B-cell survival upon oncogenic stress in the
absence or presence of Raidd, we next sorted pre-B and
immature B cells of premalignant mice and put them in culture.
Notably, B cells from non-transgenic Raidd− /−mice appeared
to be slightly less sensitive to spontaneous cell death when
compared with wt (Figure 2b). As reported before,30–32 B cells
derived from Eμ-Myc mice died more rapidly when compared
with the non-transgenic counterparts but additional lack of
Raidd had no relevant impact (Figure 2b). Similarly, Raidd
deficiency had no impact on homeostatic or c-Myc-driven
Figure 1 Loss of Raidd does not impact on DNA-damage-induced tumor
formation. (a) Kaplan–Meier plot of tumor-free survival in response to repeated low-
dose γ− irradiation (4 × 1.75 Gy) of wt (n= 8, mean= 207 days), Raidd− /− (n= 8,
mean= 190 days) and p53+/− mice (n= 5, mean= 115 days). (b) Kaplan–Meier
analysis of 3-methylcholanthrene (3-MC)-treated mice. Wild type (n= 6,
median= 132 days); Raidd− /− (n= 10, mean= 131 days); p53+/− (n= 5,
mean= 79 days). Wild-type mice injected with vehicle only (n= 3) were used as
solvent controls
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B-cell proliferation, as assessed by BrdU-incorporation
analysis in immature CD19+IgM− and CD19+IgM+ B cells
from bone marrow or spleen of premalignant mice (Figure 2c).
Next, cohorts of Eμ-Myc, Eμ-Myc/Raidd− /− and, for
reference, Eμ-Myc/Casp-2− /− mice were monitored for
tumor onset. Strikingly, although loss of Caspase-2 leads to
accelerated disease onset (mean survival: 101 d), loss of
Raidd had no effect, when compared with Raidd-proficient
Eμ-Myc mice presenting with a mean survival: 128 versus
124 days (Figure 3a). White blood cell counts and
tumor burden were also comparable between genotypes
(Supplementary Figures 1a and b).
Tumors were subsequently classified by flow cytometry as
either pre-B cell (IgM−), immature B cell (IgM+), mixed (IgM+/− )
or as early hematopoietic progenitor-derived lymphomas
(B220+CD4+). χ2 analysis confirmed differential distribution
between wt and Casp-2− /− tumors (P= 0.043), as reported
before4 but no significant differencewas noted betweenwt and
Raidd− /− tumors (Figure 3b).
Further, in lymphoma cells derived from Eμ-Myc/Raidd− /−
mice, cell cycle distribution (Figures 4a and b), spontaneous
(Figure 4c) and drug-induced cell death (Figure 4d) were
monitored and found comparable to their wt counterparts.
Notably, Caspase-2-deficient tumors showed again an
Figure 2 B-cell subset composition, proliferation and cell death responsiveness in premalignant Raidd− /− mice. (a) The development and the distribution of B cells in bone
marrow and spleen was assessed in 4-week-old Eμ-Myc transgenic mice lacking or expressing Raidd. Single-cell suspensions of the organs were counted and stained with cell
surface marker-specific antibodies and analyzed by flow cytometry. Bars represent means (n= 3-5 per genotype)± S.E.M. (b) Sorted premalignant B cells (pre-B from bone
marrow, CD19+IgM−CD43− or immature B cells CD19+IgMlow from spleen) were analyzed for spontaneous death after 6, 24 and 48 h using Annexin-V plus 7-AAD staining in a
flow cytometer. Symbols represent means of n= 3-5 per genotype±S.E.M. (c) Proliferation rates were quantified 4 h after a single injection of BrdU in bone-marrow-derived
pro/pre-B cells, (CD19+IgM−) or (CD19+IgM+) B cells from spleen. Bars represent means (n= 3-5) per genotype± S.E.M.
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increase in phospho-Histone H3 staining, suggesting per-
turbed cell cycle control (Figure 4b). In linewith a lack of impact
on tumor latency, loss of Raidd did not release the pressure to
inactivate p53, a known secondary hit, usually observed in
about 25% of all Eμ-Myc lymphomas.36 Inactivation of p53, as
assessed by western blotting for p53 and p19ARF, was seen
at similar rates in Eμ-Myc (26%, n=11) and Eμ-Myc/Raidd− /−
(27%, n= 19) tumors (Supplementary Figures 1c and d).
Overall, these data demonstrate that the adaptor protein
Raidd is not limiting Myc-driven tumorigenesis thereby
uncoupling the tumor-suppressor function of Caspase-2 from
Raidd-dependent autoactivation and the oncogenic potential
of Pidd1 from Raidd-modulated NF-κB signaling.
Loss of Caspase-2 promotes aneuploidy. As Caspase-2
has been implicated in mediating mitotic catastrophe as a
response to DNA-damage after failed cell cycle arrest37,38
and that c-Myc overexpression drives proliferation stress
leading to DNA damage,39 we investigated if lack of
Caspase-2 would influence genomic stability of normal,
premalignant or transformed cells.
First, we investigated chromosomal stability in SV40-
immortalized mouse embryonic fibroblasts (MEFs) from wt
and Caspase-2-deficient mice (Figures 5a and b). Numbers of
micronuclei, which emerge after errors during mitosis and
result in individual chromosomes or fragments outside of the
main nucleus, were significantly increased in cells lacking
Caspase-2 in comparison to wt cells. Raidd− /− MEFs did not
show increased susceptibility to micronuclei formation
(Figure 5b). Chromosomal stability was further examined by
counting chromosome numbers in metaphase spreads in
B-cell lymphomas (Figures 5c–e). Eμ-Myc transgenic B-cell
tumors deficient for Caspase-2 did show a higher variation of
chromosome numbers within individual tumor samples. Taken
together, these data are consistent with published results,
indicating that Caspase-2 acts in maintaining genomic
stability.37
In an attempt to identify potential effectors of Caspase-2 in
this process and based on the reported role of Caspase-2 in
p53 activation and target gene expression upon DNA
damage,40 we performed qPCR analysis as well as unbiased
genome-wide expression analysis comparing mRNA from
premalignant splenic IgM+D− B cells of Eμ-Myc transgenic
animals deficient or proficient for Caspase-2 or Raidd. We
started by comparing expression levels of mRNAs of p21,
Noxa and Puma by qRT-PCR, anticipating that c-Myc-driven
p53 activation would result in reduced expression of these
targets in the absence of Caspase-2.40 This, however, was not
the case, or at least the noted differences did not reach
statistical significant differences (Supplementary Figure 2).
Comparison of gene-chip data revealed only few candidates,
including Fbxw10, Fgd6, Hist3h2a, Hmha1, Igf1R, Lyrm7,
RhoBTB1, Slc25a13 and Zfp39, that were deregulated more
than twofold in the absence of Caspase-2 or RAIDD when
compared with wt (Supplementary Figure 2). Only one of
these candidates, that is, RhoBTB1, was subsequently
confirmed by qPCR analysis. However, as RhoBTB1 is
unlikely related to genomic stability this was not followed up
in detail during the course of this study. This indicates that
there are no significant changes, at least in the premalignant B
cells analyzed that may contribute to the genomic instability
observed following loss of Caspase-2.
Discussion
In this study, we investigated the relevance of Raidd in
tumorigenesis sparked by its function as an adaptor protein for
Caspase-2 and Pidd1, both being reported to influence
tumorigenesis in vivo. Caspase-2 is well characterized as a
tumor-suppressor gene in various mouse cancer models,3–7
whereas loss of Pidd1 leads to a delayed tumor onset upon
c-Myc overexpression.4 Our data demonstrate that loss of
Raidd has no influence on the development of radiation-
induced thymic lymphomas or chemically induced fibrosarco-
mas (Figure 1). Although the mean latency in the absence of
Raidd appeared to be shortened when compared with wt (190
versus 205 days), statistical significance was not reached,
possibly due to the rather small cohort size, requiring more
detailed follow up. Yet, these observations are similar to the
published results in Caspase-2- and Pidd1-deficient mice4
Figure 3 Suppression of c-Myc-induced B-cell lymphoma formation by Caspase-
2 does not depend on Raidd. (a) Lymphoma-free survival of Eμ-Myc (n= 37,
mean= 128 days), Eμ-Myc/Raidd− /− (n= 43, mean= 124 days) and Eμ-Myc/
Casp-2− /− mice (n= 15, mean= 101 days). (b) Flow cytometric analysis of tumor
immunophenotype. A comparison of the frequency of the different immunophenotype
across genotypes by Chi-square test revealed differences between wt and Casp-2− /−
tumors (P= 0.043), whereas the overall distribution between wt andRaidd− /− tumorswas
not significantly different (P= 0.1)
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and exclude a role of any of the PIDDosome components in
these DNA-damage-driven models of cancer.
Strikingly, Raidd deficiency also had no influence on tumor
latency in c-Myc-driven B-cell lymphomas (Figure 3a), con-
trasting the findings with Caspase-2- or Pidd1-deficient mice,
where Caspase-2 acts as a tumor suppressor and Pidd1 as a
tumor promoter in this model. Our data show that loss of Raidd
is dispensable for the development of B-cell lymphomas in the
Eμ-Mycmousemodel and that Raidd deficiency has no impact
on the development, proliferation and cell death of premalig-
nant and transformed cells (Figure 2). The results thus indicate
that Caspase-2-mediated tumor suppression is independent
of both Pidd1 and Raidd. This is in line with the idea that
Caspase-2 autoactivation can occur without the need for
additional accessory proteins.14–16 Consistent with our con-
clusion, it has been shown that Caspase-2 indeed appears to
be able to exert biological effects that do not depend on either
catalytic activity or interaction with RAIDD or PIDD1,
exemplified by translational control of p21 levels.41 As reduced
levels of p21 by Caspase-2 knockdown sensitizes Hct116
colon cancer cells to irradiation-induced cell death,41 one may
speculate that a similar effect may account for the tumor-
suppressive effect noted in Eμ-Myc/Casp-2− /− mice. How-
ever, deficiency inCdkn1a, encoding for p21, has no impact on
the tumor latency in Eμ-Myc mice,42 excluding this possibility.
However, it remains possible that not all aspects of Caspase-2
biology are conserved between mice and humans, as
previously also recognized for the Caspase-2-dependent
Chk1-suppressed cell death pathway that appears functional
in human cancer cells but not in mouse lymphocytes or MEF.43
It is also not easy to reconcile the findings connecting
deregulated expression of RAIDD in human cancer
Figure 4 Normal cell cycle distribution and tumor cell apoptosis in Eμ-Myc tumor cells lacking Raidd. (a) Cell cycle phases G1 (black), S (dotted) and G2/M (white) of
lymphoma cells were assessed ex vivo by intracellular DNA content analysis in tumors derived from Eμ-Myc (n= 21), Eμ-Myc/Raidd− /− (n= 22), Eμ-Myc/Casp-2− /− (n= 10)
mice. (b) To define the percentage of cells in M-phase, ex vivo tumor cells were stained with an antibody specific for the phosphorylated variant of Histone H3 (pH3) and propidium
iodide. Bars represent mean values of pH3+ cells± S.E.M. Eμ-Myc (n= 17), Eμ-Myc/Raidd− /− (n= 11) Eμ-Myc/Casp-2− /− (n= 5). (c) Apoptosis in situ was assessed by Sub-
G1 analysis of freshly isolated lymph node tumor masses followed flow cytometric analysis (wt n= 24, Raidd− /− n= 22, Casp-2− /− n= 10) mean values± S.E.M. (d) Freshly
isolated lymphoma cells were cultivated on feeder cells for 24 h and were either left untreated (upper left graph) or exposed to increasing doses of the indicated chemo-
therapeutics. Cell death was assessed by Annexin-V/7-AAD staining combined with anti-CD19 to identify B cells. Symbols represent mean values, n43–7 for each
genotype± S.E.M.
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development and drug-resistant phenotypes10,25–27 with our
data presented here. Although deregulated expression of
RAIDD levels in cancer may be a bystander effect, for
example, due to de-differentiation of cancer cells or deregula-
tion of multiple signaling pathways ultimately also impacting
on RAIDD mRNA levels, the differences in drug resistance, or
lack thereof (our study) may simply be due to cell type-specific
differences, the oncogenic drivers or the triggers used.
Investigating the role of PIDDosome components in other,
preferentially, non-hematological tumor models will shed
some light.
Prior work linked loss of Caspase-2 to chromosomal and
genomic instability as a possible driver of accelerated
transformation.37 Consistently, SV40 MEFs and c-Myc trans-
genic B cells lacking Caspase-2 showed significantly higher
levels of micronuclei formation and numbers of chromosomes
in metaphase spreads diverted more strongly from the normal
number. However, our analysis of chromosome numbers in
Eμ-Myc B-cell tumors did not show a direct increase in the
frequency of aneuploidy in cells lacking Caspase-2. Instead,
we found that the aneuploid cells present in the Caspase-2-
deficient tumors showed a greater variation of chromosome
numbers in the same tumor sample. Furthermore, our data
show that the level of high-grade aneuploidy (i.e., a loss or gain
of more than 10 chromosomes) was greater in Caspase-2− /−
tumors. Together, these results clearly support a possible role
of Caspase-2 inmaintaining genomic integrity, whereas loss of
the adaptor protein Raidd is dispensable for genomic stability
(not shown).
As it is difficult to connect these observations with known
substrates of Caspase-2 and the analysis of representative
p53-induced genes failed to support impaired murine double
Figure 5 Caspase-2-loss leads to increased micronuclei formation and aneuploidy. (a) Representative images of micronuclei formation in SV40 MEFs of the indicated
genotypes stained with 4′,6′-diamidino-phenylinodole. Arrows indicate micronuclei formation in wt MEFs. Scale bars= 5 μm. (b) Quantification of data assessed in a. A minimum
of 300 cells per genotype was evaluated. Wt versus Casp-2− /− (P= 0.03; Student's t-test). Bars represent mean of n44–6 for each genotype±S.E.M. (c) Representative
images of chromosome spreads using freshly isolated Eμ-Myc lymphoma cells. Metaphase spreads are showing representative euploid (left panel) or aneuploidy karyogramms
ranging from low (middle panel) to high-grade (right panel). Scale bar= 5 μm. A minimum of 50 spreads per genotype was evaluated. (d) Variation of counted chromosome
numbers within single tumors from Eμ-Myc (n= 13) versus Eμ-Myc/Casp-2− /− (n= 10) mice (P= 0.0029; Student's t-test). (e) Quantification of the variance of chromosome
numbers in tumors derived from indicated genotypes. A χ2 test showed a significant difference between wt and Casp-2− /− (Po0.0001)
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minute 2 activity, as reported in cisplatin-treated lung cancer
cells,40 we performed whole transcriptome analysis on
premalignant Eμ-Myc pre-B cells lacking or expressing
Caspase-2 (or Raidd). However, we again failed to identify
possible candidates that may be involved in the observed
tumor-suppressor phenotype and established p53 targets
were also not deregulated (Supplementary Figure 2). Hence, it
remains possible that the phenomenon of reduced p53
activation in the absence of Caspase-2 is cell type-specific,
for example, in lung epithelium,40 and/or a particular second-
ary hit, or a fully transformed cellular state.37 Consistent with
the latter scenario, we previously reported on a reduced
selective pressure to inactivate p53 in Eμ-Myc lymphomas
lacking Caspase-2.4
In summary, our data suggest that Raidd does not influence
the development of tumors after DNA-damage stress or the
overexpression of oncogenes. This is in strong contrast to the
opposing effects of its putative interaction partners, Caspase-
2 or Pidd1.3,4 Hence, the function of Raidd as a ‘direct activator
of Caspase-2’ needs to be re-considered, at least in the
context of Eμ-Myc-driven tumorigenesis and justifies the
search for additional activators as well as substrates of
Caspase-2 to understand its tumor-suppressive function at
the molecular level.
Materials and Methods
Mice. All animal experiments were performed in accordance to the Austrian
legislation (BGBl. Nr. 501/1988 i.d.F. 162/2005, # BMWF-66.011/0137-II/10b/2009).
The generation and genotyping of Casp-2− /−, Raidd− /−, p53+/− and Eμ-Myc
transgenic mice have been described elsewhere.34,44–46 All mice used for the
experiments were on an inbred C57BL/6 background.
Tumorigenesis induced by DNA damage. To induce thymic lymphomas,
mice at the age of 4 weeks irradiated with 1.75 Gy in a linear accelerator once per
week for 4 weeks. Muscular sarcoma formation was induced by a single 200 μl intra
muscular injection of 1 mg 3-MC per mouse (Sigma, Vienna, Austria), dissolved in
sesame oil. Mice treated with sesame oil alone (vehicle) served as a control.
Cell culture and reagents. Primary tumor cells derived from Eμ-Myc,
Eμ-Myc/Raidd− /−, Eμ-Myc/Casp-2− /− and Eμ-Myc/Pidd1− /− mice were cultured
in DMEM (PAA, GE Healthcare, Pasching, Austria), supplemented with 10% FCS
(PAA) Pen/Strep (Sigma), 250 μM L-Glutamine (Gibco/Invitrogen, Vienna, Austria)
and 50 μM 2-mercaptoethanol (Sigma) and were kept on irradiated Bcl-2-
overexpressing NIH-3T3 feeder cells. Tested agents and concentrations were:
Etoposide (0.01–1 mg/ml), Dexamethasone (109–107 M), Paclitaxel (0.5–50 mM),
Thapsigargin (0.5–50 ng/ml) and Doxorubicin (4–400 ng/ml; all from Sigma). FACS-
sorted pre-B, immature and IgM+ B cells were cultured in DMEM with supplements
and spontaneous cell death was monitored over time.
Flow cytometric analysis and cell sorting. Tumors were analyzed by flow
cytometry using the following cell surface markers for (a) B cells: RA3-6B2, anti-B220;
R2/60, anti-CD43; II/41, anti-IgM; 11/26C, anti-IgD; MB19-1, anti-CD19; 53-7.3, anti-
CD5 and B3B4, anti-CD23; 7E9, anti-CD21 (BioLegend, Fell, Germany); and (b)
T cells: GK1.5, anti-CD4; H57-597, anti-TCRb (all from eBioscience, Vienna, Austria)
and 53-6.7, anti-CD8; (from BD Pharmingen, San Diego, CA, USA). Biotinylated
antibodies were monitored with streptavidin-RPE (DAKO, Vienna, Austria) or
streptavidin-PE-Cy7 (BD Phamingen). Using a FACSVantage cell sorter (Becton
Dickinson, Heidelberg, Germany) premalign pre/pro-B cells (B220+/IgM−) or immature
(IgM+/IgDlow) and mature (IgM+/IgDhigh) B cells were isolated and sorted from bone
marrow and spleen, respectively. Flow cytometry data were analyzed using Cyflogic
free ware and FlowJo (Ashland, OR, USA).
Immunoblotting. Proteins were extracted from tumor cells for 1 h on ice in
protein lysis-buffer.36 Insoluble debris was cleared by centrifugation for 5 min at
13 000 r.p.m. and 4 °C. For evaluation of the p53 status of tumor cells 30 μg
protein/lane was separated by SDS-PAGE, transferred to a nitrocellulose membrane
and probed with rat anti-p19/ARF (5-C3-1; Santa Cruz Biotechnology, Szabo-
Scandic, Vienna, Austria) or mouse anti-p53 antiserum (1C12; Cell Signaling, New
England Biolabs, Frankfurt, Germany). Comparability of protein loading was
assessed by re-probing membranes with an antibody recognizing GAPDH (Sigma).
Horseradish peroxidase-conjugated sheep anti-rat Ig antibodies (Jackson Research,
Vienna, Austria), goat anti-rabbit or rabbit anti-mouse antibodies (DAKO) were used
as secondary antigens. Antibody binding was detected using enhanced
chemiluminiscence (Amersham, Freiburg, Germany) system.
Cell cycle analysis. Cell cycle analysis was based on fixing lymphoma cells in
70% ethanol and staining with PI (propidium iodide at 40 μg/ml; Sigma). To analyze
the percentage of cells in M-phase, ethanol-fixed lymphoma cells were
permeabilized using Triton-X (0.25%, Sigma) for 15 min on ice and co-stained
with phosphorylated H3 (Ser10; Cell Signaling) and PI. Distribution of cell cycle
phases was analyzed using a FACScan cell cytometer (BD, Heidelberg, Germany).
BrdU incorporation. Cell proliferation of immature (CD19+IgM−) and mature
(CD19+IgM+) B cells in premalignant 4-week-old mice was assessed by injecting
1 mg BrdU/mouse i.p. Four hours later, primary cells derived from bone marrow and
spleen were isolated and stained for BrdU incorporation using the BrdU/APC flow kit
(BD, Vienna, Austria) according to the manufacturer’s recommendation. Samples
were analyzed using FACS-Calibur (BD).
Cell viability assay. Tumor cells were co-stained with Annexin-V-FITC
(1 : 1800 in Annexin-V-binding buffer; BD) and 7-AAD (1 μg/ml, Sigma) and
spontaneous cell death was analyzed by subsequent flow cytometric analysis.
Cytogenetic analysis. Micronuclei were examined by seeding 2 × 105 MEF
on a sterile coverslip treated with cytochalasin (4 μg/ml) for 16 h before fixation in
PTEMF fixative47 for 10 min and staining with 4′,6′-diamidino-phenylinodole.
A minimum of 300 cells per condition and genotype were screened for micronuclei
under a ZEISS IMAGER Z1 Microscope and Zeiss EC Plan-NEOFLUAR 40 × /0,75
Ph2 objective using AxioVision Release 4.8.2 imaging software (Zeiss, Oberkochen,
Germany).
Chromosome spreads from freshly isolated tumors were generated by incubating
1 × 106 lymphoma cells in media containing 1 μM nocodazole (Sigma) for 5 h at 37 °C
in a CO2 incubator. After collecting and washing the cells in PBS, the pellet was
resuspended in 5 ml 0.075 M KCl (Merck) and incubated for 5 min at 37 °C. Then 1 ml
Carnoys fixative (Methanol:Acetic Acid= 3:1) was added. Cells were spun down
(1200 g for 3 min) and fixed in 1 ml Carnoys fixative (repeated three times). Cells were
added drop-wise (from ∼ 50 cm hight) onto a coverslip, air dried and stained with
4′,6′-diamidino-phenylinodole. A minimum of 50 chromosome spreads per tumor
sample was analyzed at × 100 magnification.
qRT-PCR analysis. RNA was isolated using TRIzol (Invitrogen) and
transcribed into cDNA (Omniscript, Qiagen, Hilden, Germany) using random
hexamer primers after DNAse digestion (Promega, Mannheim, Germany). cDNA of
interest was amplified using primers listed in Supplementary Table 1 and
2 × DyNAmo Color Flash SYBR Green Master Mix (Thermo Scientific, Vienna,
Austria) in an Eppendorf Mastercycler ep realplex2 cycler. Relative expression of
target/housekeeper was calculated using the delta-CT method.
Microarray data set generation and analysis. Microarray data for gene
expression were obtained using Affymetrix MoGene 1.0 ST v.1 arrays (Affymetrix, Santa
Clara, CA, USA). Sample preparation was performed according to the manufacturer’s
protocol. In brief, 250 ng of high-quality RNA per sample were processed using the
Ambion Affymetrix GeneChip WT Expression Kit (Part no. 308 4411974, Ambion/Thermo
Scientific, Vienna, Austria) and the Affymetrix GeneChip WT Terminal Labeling Kit
(Affymetrix). The resulting biotinylated targets were hybridized in an Affymetrix
hybridization oven to a total of 14 Affymetrix MoGene 1.0 ST v.1 microarrays, which
were then washed and stained in an Affymetrix fluidic station 450. Raw fluorescence
signals were recorded in an Affymetrix scanner 3000 and image analysis was made with
the Affymetrix GeneChip Command Console software.
Subsequent analyses have been performed in R (version 3.0.2) using packages
from the Bioconductor project48 (version 2.13, BioConductor project: Fred Hutchinson
Cancer Research Center, Seattle, WA, USA). The raw microarray data were pre-
processed using ‘generalgcrma’ package49 and our custom transcript-level ‘CEL
definition file’ (CDF) as described in Bindreither et al.50 Transcripts for all genes have
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been defined using Ensembl version 71 (EMBL-EBI, Wellcome Trust Genome
Campus, Hinxton, UK). The CDF contained a total of 63 455 probe sets for 22 991
genes. Background adjustment, normalization and summarization of the microarray
data were performed using the GCRMA method.51 Further, a single-probe set per
gene was selected as following: (a) if there were probe sets with more than 5 probes,
only those were considered for further analysis, (b) if any of considered probe sets
represented protein coding transcripts, the list of probe sets was limited to such and
(c) the probe set which had the highest multiple of average expression and standard
deviation across all samples was chosen for expression analysis.
Differential expression analysis was performed using limma package.52 P-values
were adjusted for multiple hypotheses testing correction by method of Benjamini and
Hochberg.53 Genes with adjusted P-valueo0.05 and absolute log2 fold change41
were considered to be significantly regulated.
The raw and pre-processed microarray data have been submitted to the Gene
Expression Omnibus (accession number GSE64920).
Statistical analysis. Statistical analysis was performed using unpaired
Student’s t-test or ANOVA with Student–Newman–Keuls as post hoc test.
Comparison of Kaplan–Meier survival plots was performed using a log-rank test
and for evaluation of statistical difference in frequency distributions the χ2 (Fisher’s
exact) analysis algorithm was used. P-values ofo0.05 (*) or Po0.001 (**) indicate
significant differences.
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